The 36-month beta value for VIR is at 1.23. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 5 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for VIR is 89.08M, and currently, shorts hold a 12.93% of that float. The average trading volume for VIR on June 13, 2025 was 1.35M shares.
VIR) stock’s latest price update
The stock price of Vir Biotechnology Inc (NASDAQ: VIR) has plunged by -0.57 when compared to previous closing price of 5.25, but the company has seen a 1.36% gain in its stock price over the last five trading sessions. businesswire.com reported 2025-05-28 that SAN FRANCISCO–(BUSINESS WIRE)–Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on Tuesday, June 10 at 1:00 p.m. PT / 4:00 p.m. ET in Miami Beach, Florida. A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be ar.
VIR’s Market Performance
Vir Biotechnology Inc (VIR) has experienced a 1.36% rise in stock performance for the past week, with a 11.06% rise in the past month, and a -25.43% drop in the past quarter. The volatility ratio for the week is 1.41%, and the volatility levels for the past 30 days are at 3.33% for VIR. The simple moving average for the last 20 days is 5.25% for VIR stock, with a simple moving average of -30.85% for the last 200 days.
Analysts’ Opinion of VIR
Many brokerage firms have already submitted their reports for VIR stocks, with JP Morgan repeating the rating for VIR by listing it as a “Neutral.” The predicted price for VIR in the upcoming period, according to JP Morgan is $9 based on the research report published on January 29, 2024 of the previous year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see VIR reach a price target of $14, previously predicting the price at $23. The rating they have provided for VIR stocks is “Neutral” according to the report published on September 08th, 2023.
JP Morgan gave a rating of “Overweight” to VIR, setting the target price at $34 in the report published on March 06th of the previous year.
VIR Trading at -3.04% from the 50-Day Moving Average
After a stumble in the market that brought VIR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.88% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VIR starting from GEORGE SCANGOS, who proposed sale 19,957 shares at the price of $5.41 back on Jun 11 ’25. After this action, GEORGE SCANGOS now owns shares of Vir Biotechnology Inc, valued at $108,037 using the latest closing price.
GEORGE SCANGOS, the Former Director of Vir Biotechnology Inc, proposed sale 50,000 shares at $5.48 during a trade that took place back on Jun 10 ’25, which means that GEORGE SCANGOS is holding shares at $273,885 based on the most recent closing price.
Stock Fundamentals for VIR
Current profitability levels for the company are sitting at:
- -30.81 for the present operating margin
- 0.69 for the gross margin
The net margin for Vir Biotechnology Inc stands at -29.44. The total capital return value is set at -0.52. Equity return is now at value -44.59, with -37.25 for asset returns.
Based on Vir Biotechnology Inc (VIR), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -4.32.
Currently, EBITDA for the company is -537.61 million with net debt to EBITDA at 0.3. When we switch over and look at the enterprise to sales, we see a ratio of 27.73. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.79.
Conclusion
In conclusion, Vir Biotechnology Inc (VIR) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
